FindTrial
Sign In

Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients

Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients - Virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026640
Enrollment
300
Registered
2017-03-23
Start date
2017-01-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Treat with Ombitasvir/Paritaprevir /Ritonavir/Ribavirin combination therapy.

Sponsors

Nipppon Medical School Chiba Hokusoh Hospital
Lead Sponsor
Nippon Medical School Hospital Nippon Medical School Musashi Kosugi Hospital The Jikei University Hospital Otakanomori Hospital Hakujikai Healthcare foundation Tokyo Metropolitan Bokutoh Hospital Tokyo Medical University Ibaraki Medical Center Shinmatsudo Central General Hospital Japanese Red Cross Narita Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Case of introducing ombitasvir/paritaprevir/ritonavir/ribavirin combination therapy for Genotype 2 type C chronic liver disease

Exclusion criteria

Exclusion criteria: 1History of allergy to Ombitasvir/Paritaprevir /Ritonavir/Ribavirin 2Liver cirrhosis 3Patients with creatinine clearance less than 50 ml / min 4Pregnant woman or lactating mother 5Hepatocellular carcinoma, or other malignant tumor 6Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

MeasureTime frame
Sustained virological response rate—

Secondary

MeasureTime frame
1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration.—

Countries

Japan

Contacts

Public ContactTomomi Okubo

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

atsukawa-nms@umin.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026